John Dwyer joins Touchlights board of directors

Hampton, UK – 03 December 2020 – Touchlight, a biotechnology company focused on the discovery and development of DNA-based genetic medicines, today announces the appointment of John Dwyer to the Company’s Board of Directors as a Non-Executive Director.

John spent over 20 years as partner at PwC UK, where he led the Global Deals Business and sat on the Executive Board as Head of Deals with responsibility for the TS, Restructuring, Corporate Finance and Forensics businesses.

Since leaving PwC in 2017, John has taken up several non-executive and chair positions at Private Equity portfolio companies, as well as supporting financial transactions at firms like Pigsback.com and Exponent. John is currently Chairman of both C&N Sporting Risk, a tech-based sports business, and Irish middle-market PE firm Renatus.

Jonny Ohlson, Executive Chairman of Touchlight, commented: “John brings more than 30 years of distinguished experience in leadership, commercial strategy, finance and operations. We are pleased that he has decided to join our board and confident that his support will help Touchlight achieve our long-term objectives.”

Commenting on his appointment, John Dwyer said: “I’m delighted to join the Board of Directors of such an innovative company as Touchlight. With nucleic acid vaccines growing in importance by the day, this might be the most exciting time to join a company in this field. I believe that doggybone DNA has an immense potential and look forward to leveraging my experience to assist as Touchlight advances to the next level.”

- ENDS -

About Touchlight

Touchlight is a privately-owned CDMO based in London, U.K., focused on the provision of DNA services and manufacture of enzymatically produced doggybone DNA (dbDNA™) to enable the development of genetic medicines. Touchlight provide rapid, enzymatic DNA development and manufacturing for all advanced therapy production, including mRNA, viral and non-viral gene therapy and DNA API. dbDNA is a minimal, linear, covalently closed structure, which eliminates bacterial sequences. Touchlight’s revolutionary enzymatic production platform enables unprecedented speed, scale, and the ability to target genes with a size and complexity that is impossible with current technologies. Clients can be supported from pre-clinical through development and supply, to licencing and tech transfer for use in-house.

For more information please contact: